Email this pageA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3 and 6 mg Twice Daily) in Patients with Early Parkinson's Disease
| Purpose | This study is being conducted to see whether aplindore is safe, effective and tolerable in the treatment of subjects with the early stages of PD when taken over a period of 90 days. Also, the study will look at how aplindore affects mood, thinking and memory, behavior, impulse control and daytime sleepiness. Aplindore is considered an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration (FDA). | |||
|---|---|---|---|---|
| Details | Study Number 20082098 |
Accepts Adults? Yes |
Accepts Children? No |
Fully Enrolled? No |
| Contacts | Principal Investigator Roger Kurlan, MD |
Contact Debra Berry, 585-341-7500 |
||
For More Information
Please call the phone number listed above and the clinical trial coordinator will contact you.
